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ABSTRACT 
Throughout history, cancer has been severely plaguing mankind; the search for a 
cure to cancer had long been sought by scientists and still poses as one of the 
greatest challenges scientists have yet to overcome. Hypoxia in cells is a condition 
where there is little to no oxygen availability in its environment. In general, this event 
is detrimental since this can lead to cell necrosis or reoxygenation injuries. However, 
hypoxia, a prominent property of most solid tumors, activates the hypoxia-inducible 
factor (HIF-1) family of transcription factors that promotes angiogenesis. In this 
study, we describe the design and synthesis of small-molecule inhibitors of the HIF-1 
pathway.  
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1. INTRODUCTION 
1.1 Cancer and Hypoxia 
 
Among the persistent deadly diseases mankind still face, cancer is well known as 
one of the most varied and tenacious. Years of research have been spent towards 
the search for an effective therapy that minimizes the side effects current treatments 
come with. Although a lot has been achieved in this field, cancer is still the second 
leading cause of death in the U.S.A., second only to heart attack with 186 deaths 
occurring per 100,000 populations.1 Despite the tremendous amount of funding 
poured into research in this field, the sheer number of treatment pathways to explore 
is a daunting task.  
Hypoxia, a pathological condition in which cells are deprived of an adequate oxygen 
supply, is generally detrimental to cells and tissues since the condition will eventually 
lead to necrosis. However, cancer cells thrive under such conditions.2 Hypoxia is 
commonly seen in progressing cancer cells; the inadequate oxygen supply in cells 
causes tissue hypoxia, which leads to the activation of several pathways, and further 
development and metastasis of the tumor.2 Cancer cells under such conditions turn 
on gene expressions that can alter metabolism and promote angiogenesis through 
multiple pathways, thereby allowing cells to fuel their progression.  One example is 
the hypoxia-inducible factor 1 pathway (HIF-1). In tumor cells, the vasculature is 
different from normal cells. In addition to the normal vessels that the cells already 
have even before the tumor invades, most tumor cells develop microvessels that are 
brought about by neovascularization caused by the increased expression of genes 
that promote angiogenesis.3  
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1.2 Hypoxia-Inducible Factor 1 Pathway (HIF-1) 
 
There are three members of the hypoxia-inducible factor family whose activities rely 
upon the concentration of oxygen in the cell (Table 1).  
Table 1 Members of the Hypoxia Inducible Transcription Factor Family4 
HIF Function 
HIF-1α Alpha subunit, initiator of HIF function sequence 
HIF-1β Aryl hydrocarbon receptor nuclear translocator 
HIF-2α PAS domain protein 
HIF-2β Aryl hydrocarbon receptor nuclear translocator 2 
HIF-3α Alpha subunit (without transactivation domain) 
HIF-3β Aryl hydrocarbon receptor nuclear translocator 2 
 
 
Although each subunit shares in the response to oxygen levels in the cell, the HIF-1 
unit is the pathway that was focused on this study.  The HIF-1 complex is a basic 
loop-helix-loop motif heterodimer that is composed of two major subunits called the 
HIF-1α and the HIF-1β. Levels of HIF-1α in the cells are regulated by the presence 
or absence of oxygen while HIF-1β is constitutively expressed as aryl hydrocarbon 
receptor nuclear translocator (ARNT).5 Under normal oxygen conditions, HIF-1α gets 
hydroxylated by prolyl hydroxylase dioxygenase (PHD) at proline 564 and 402 and 
by factor inhibiting HIF-1 (FIH-1) at asparagine 803 at its oxygen degradation domain 
(ODD) with an iron (Fe2+) and 2-oxoglutarate as co-substrates.6 Furthermore, HIF-1α 
gets acetylated by ADP-ribosylation factor domain protein 1 (ARD1) at lysine 532.7,8 
This hydroxylation allows the HIF-1α to recruit the von Hippel-Lindau tumor 
suppressor protein (pVHL) that acts as an E3-ubiquitin ligase complex and tags the 
whole complex for ubiquitination and subsequent proteasomal degradation. This 
scenario is shown in Figure 1 as follows.  
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Figure 1 Proteosomal degradation pathway of HIF-1α in the presence of oxygen 
 
As depicted in Figure 2, prolyl hydroxylase loses its function to hydroxylate HIF-1α 
under hypoxic conditions. The HIF-1α subunit then gets translocated into the nucleus 
where it binds to another HIF subunit, HIF-1β.  
 
Figure 2 The HIF-1 pathway in low oxygen conditions in cells 
 
Upon binding of HIF-1α with HIF-1β to form the active transcription factor of HIF-1, 
the complex then interact with its co-activator p300/CBP and binds to hypoxic 
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response elements (HREs) to act as a transcription factor for numerous genes.9 
Because of the importance of oxygen in cells, it is not surprising that the HIF-1 
complex is a transcription factor that controls more than 2% of all human genes in 
arterial endothelial cells, directly or indirectly.8 Currently, it is well understood that the 
HIF-1 complex affects over 100 genes, most of which are vital to a cell’s survival. 
Among these genes are the vascular endothelial growth factor (VEGF), nitric oxide 
synthase (NOS), glucose transporter 1 (GLUT1), and lactose dehydrogenase A 
(LDHA).10 All of these genes that were mentioned play a massive role in the 
proliferation of a tumor cell since they fuel its growth through the formation of new 
vasculature and the creation of delivery pathways to sustain its propagation.  
 
Table 2 List of some of the genes that are activated by the HIF-1 complex10 
Genes Activated by HIF-1 Effects on Cancer Progression 
ANGPT2, C-MET, ID2, NOS, PGF, 
PDGF, SCF, SDF-1, VEGF Angiogenesis 
DEC1, MDR1 Genetic Instability 
GLUT1, GP1, HK1, HK2, LDHA, 
PDK1, PKM2 Glucose Metabolism 
TERT Immortalization 
NTSE Immune Evasion 
C-MET, EDN-1, FN-1, MMP-2, MMP-
14, PLAU, SDF1 Invasion 
ANGPT4, C-MET, CXCR4, LOX, 
MDR1, TWIST1, ZEB1 Metastasis 
CA-IX, CA-XII pH Regulation 
C-MYC, ID2, IGF-2, NOS, PDGFB Proliferation 
ABCG2, JARID1B, OCT4 Stem Cell Maintenance 
 
Many of the genes that the HIF-complex activates contribute to the defense 
mechanism of a cancer cell, as seen in Table 2. One of the most prominent features 
of the HIF-1 complex is that it activates genes that promote angiogenesis and 
glucose metabolism. Oftentimes, the cell’s environment gets further aggravated 
because of temporary occlusions and blocked vasculatures, a condition which 
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ultimately results into prompting the cell’s mechanism to begin the formation of new 
vasculature. With this acquired ability, the tumor cell can invade its surroundings to 
begin the growth of a secondary tumor and continue its malignancy. Once 
angiogenesis has commenced in tumor cells, nutrients can be supplied to these cells 
and their waste products removed. Cancer cells can also use these blood vessels to 
metastasize and pass through the blood vessels to distant sites where they can 
implant to start the growth of a new tumor. With this concurring metastasis, 
secondary tumor cells will need to develop their own ways of proliferation. In low 
oxygen conditions, tumor cells utilize anaerobic glycolysis to produce energy. 
Because of the low concentration of ATP that is produced using this cycle, tumor 
cells compensate by increasing glucose uptake through the increase of the 
production of glucose transporters such as GLUT1.8  
 
1.3 Chemo and Radiotherapy Resistance of Tumor Cells  
 
Hypoxia in tumor cells has been shown to be a contributor to chemo and 
radioresistance. A factor that contributes to chemoresistance of tumor cells is the 
apparent pH changes that occur within the environment of the cells. It was previously 
thought that hypoxia and acidosis in tumor cells concomitantly occur because of the 
lactate produced when oxidative phosphorylation gets switched to anaerobic 
glycolysis; but this is not the case.11 It was shown that when tumor cells in hypoxic 
conditions are subjected to both buffered and non-buffered media, the cells survived 
in the buffered medium and the cells induced apoptosis in the non-buffered medium. 
One can infer from this study, therefore, that in hypoxic cells that are not 
experiencing acidosis, tumor cells can survive freely and have advantage over 
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healthy cells since programmed cell death would not commence.12 Most anti-cancer 
drugs that are on the market require molecular oxygen to function. Drugs such as 
melphalan, an antitumor alkylating agent, have a higher chance of permeating the 
tumor cells and interacting with their DNA under normoxic conditions rather than a 
hypoxic tumor cell.13 This phenomenon was seen when tumor cells were introduced 
into hypoxic conditions with drugs such as doxorubicin, another widely used 
anticancer drug. When doxorubicin was introduced to both normoxic and hypoxic 
tumor cells, the survival rate of the latter was increased.13 Furthermore, when cancer 
cells experience acidosis, their microenvironment becomes an area where cellular 
uptake of drugs is decreased. The acidic extracellular environment of cancer cells 
contributes to chemoresistance due to some anticancer drugs having a weakly basic 
character (i.e. doxorubicin, mitoxantrone, vincristine and vinblastine).14 As mentioned 
earlier, cancer cells have abnormal vasculatures and as such, there is limited blood 
flow to most areas in the cell that experiences hypoxia. Because of this, nutrients 
and drugs find it hard to reach these sites and thus contribute to chemoresistance.14 
Another common way to treat cancer is through the use of radiotherapy. 
Radiotherapy does damage to tumor cells through induction of oxidative stress. 
When a malignant cancer cell is irradiated, either the DNA molecule itself or its 
environment that contains water molecule produce reactive oxygen species (ROS) 
that induce oxidative stress in the cell that can lead to DNA damage.15 However, 
upon radiation and production of ROS, a study found that radiation itself induced 
HIF-1 activity in the tumor cells that led to the expression of VEGF and basic fibrolast 
growth factor (bFGF) that enhances endothelial cell radioresistance.16  
Because of these reasons, the HIF-1 complex is a very attractive target for cancer 
therapy. 
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1.4  HIF-1 Inhibitors 
 
Throughout the years since its discovery and evident route for anticancer therapy, 
many have pursued HIF-1 complex inhibitors. Most of the advances in this endeavor 
have been focused on the synthesis of small molecules that inhibit the HIF-1 
pathway. Many of the therapeutic candidates that have been synthesized and are 
currently in preclinical studies have the target of altering the concentration of the 
HIF-1α subunit by interfering with its translation, degradation or its transcriptional 
activity.17 One of the major subclasses of HIF-1 inhibitors consists mainly of 
heterocycle-based inhibitors that are derived from natural products.  
To start this project, the laboratory of Dr. Erwin Van Mein in Emory University started 
the search for a small-molecule that shows potential HIF-1 complex inhibition using 
combinatorial chemistry. Some 10,000 compounds were screened from a 2,2-
dimethylbenzopyran library. The chosen compounds were tested against human 
glioma cells that were transfected with an HRE-alkaline phosphatase reporter gene 
to measure their IC50 values.6 From this library, a potential inhibitor, KCN-1 (Figure 
3), was found, and was proven to be efficacious in inhibiting cancer growth.18 
 
Figure 3 Molecular structure of KCN-1 
 
Although most HIF-inhibitors on the market affect the HIF-1α subunit by way of the 
HIF-1α’s concentration in the cell, KCN-1 was seen to affect the complex differently. 
O
N S
OMe
OMe
IC50: 0.59 µM
cLogP: 5.20
O O
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Through mechanistic studies, it was seen that KCN-1 interrupts the association of 
the HIF-1α /HIF-1β heterodimer from its interaction with its co-activators p300/CBP.6 
This insight could lead to the synthesis of HIF-inhibitors that affect the HIF-1 complex 
through a different pathway.  
 
2. DESIGN AND STRUCTURE OF INHIBITORS 
2.1 KCN-1 Analogues 
 
The main goal of the project was to synthesize more potent KCN-1 analogues with 
low to no toxicity. As seen in Figure 3, KCN-1 was divided into four regions for 
analogue synthesis: the benzopyran moiety (red), the nitrogen linker (blue), the 
sulfonamide moiety (green) and finally, the dimethoxy moiety (purple). Most of the 
changes done in this study were mostly focused on altering the nitrogen linker and 
the dimethoxy moiety in the hopes of synthesizing a more potent compound. Within 
this class, the most potent HIF-1 inhibitor previously synthesized by our group had 
an IC50 of 0.25 µM (SRIV-64b, Figure 4) and was tested against KCN-1, showing a 
threefold increase in potency.6 With this lead, the synthesis of new HIF-1 
sulfonamide analogues commenced.  
 
Figure 4 Molecular structure of SRIV-64b 
 
 
 
 
N
O
N S
OMe
OMe
IC50: 0.28µΜ
cLogP: 3.53
O O
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2.1.1 Chemistry of Sulfonamide Analogues 
 
The synthesis of such compounds started with the benzopyran moiety. With a 
hydroxyaryl aldehyde and a tertiary alkyl halide as a starting material, the two 
compounds were condensed in the presence of a non-nucleophilic base such as 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in an SN1 fashion (Equation 1).  
 
 
After this step, the cyclization of the ring occurred by subjecting the condensed 
product to basic conditions at 170 oC. (Equation 2).  
 
 
 
This ring closure is afforded through a Claisen rearrangement whose mechanism is 
shown in Figure 5. Once the allene moiety is formed, the oxyanion attacked the sp2 
carbon to form the benzopyran moiety. However, the oxyanion could have attacked 
the sp carbon of the allene to form a benzofuran ring. The preference of the reaction 
to form the benzopyran ring can be rationalized by the angle of attack by the 
nucleophile. 
 
HO
CHO
Cl
DBU, ACN
0oC to r.t., 6h CHO
O
1
(1)
CHO
O N,N-dimethylaniline
170oC, 12h CHO
O
2
(2)
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Figure 5 Mechanism of the Claisen rearrangement to close the benzopyran ring 
 
 
 
Figure 6 Two possible products from the Claisen rearrangement 
 
If one were to analyze this mechanism using Baldwin’s rules of ring closure, it can be 
seen that both products shown in Figure 6 could form. However, if the orientation 
between the oxyanion nucleophile and the electrophilic allene carbon were to be 
considered, the main reason as to why the formation of the benzopyran path (green) 
is favored over its counterpart is probably due to the angle from which it attacked the 
electrophile and how the dimethyl group faced the anionic specie. The dimethyl 
group was orthogonal to the sp-carbon in this case, which exposed the terminal 
carbon (sp2) of the allene more to a nucleophilic attack.  
OHC
O
OHC
O
H
C
N
OHC
O
C
N
H
O
OHC
Reaction Mechanism:
O
OHC
OHC
O
C
N
H
OHC
O
6-endo-trig product5-exo-dig product
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After the synthesis of the left hand core, the nitrogen linker was introduced by 
reacting either an aliphatic or aromatic primary amine with the aldehyde to produce a 
secondary amine through reductive amination (Equation 3). The chosen nitrogen 
moieties for this scaffold in this study were aniline and cyclobutylamine (scaffolds for 
KCN-1 (X = C) and SR-IV-64b (X = N) respectively). Once the secondary amine had 
been formed, the next step was the introduction of the sulfonyl moiety by a 
sulfonylation reaction (Equation 4).  
 
 
Scheme 1 Reductive amination and sulfonylation reaction with the different substitutions made on the 
scaffold 
 
Different sulfonylation reactions were done to produce a variety of sulfonamide 
analogues (Scheme 1). The main group that was focused on in this scaffold was the 
O
CHO
1) R1-NH2, InCl3
2) NaCNBH4
MeOH, r.t., overnight
O
H
N
R1
R1 =
(3)
O
H
N
R1
O
N
S
R1
R2DCM, r.t., overnight
R2-SO2Cl, K2CO3
R2 = OCF3
O
N
F
F
CN
OEt
(4)
O O
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right hand core (sulfonyl moiety) to diversify the SAR studies done of previous 
analogues.  
 
2.2 Structure Activity Relationships (SAR) of Previously Synthesized 
Analoguesa 
 
 
Figure 7 General scaffold of sulfonamide analogues 
 
As seen in Figure 7, the analogues synthesized follow a general scaffold in this 
study. The previous SAR profile demonstrated that on the left hand core, 
benzopyrans and pyrano [3,2b] pyridines showed an increase in inhibition activity. 
Although other fused rings are tolerated, it did not show an increase in potency as 
compared to KCN-1. The geminal dimethyl moiety on both the benzopyran and 
pyridinyl rings also showed significance since their loss in the scaffold led to a 
decrease in activity. For the nitrogen linker, the activity was at its best when the 
substituents on the nitrogen were an aromatic ring and cycloalkyl rings of less than 
6-carbons in size; furthermore, it was seen that short alkyl chains were tolerated as 
well. It was also generally seen that the sulfonamide group itself (N-SO2) was crucial 
for biological inhibition. Lastly, for the right hand core, it was seen that the activity 
was more pronounced if an aromatic group was present that had substituents on the 
para position as opposed to meta substituted aromatic rings.6 In choosing the 
variation that were to be made with the compounds, the Lipinski’s Rule of Five was 
                                                
a All of the SAR studies were obtained from Dr. Suazette Mooring’s studies.6 
N
S
R2R1 R3
O O
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selected to be the criteria to be followed. This allowed our group to synthesize 
compounds that followed general rules when considering what functional groups that 
were chosen to be introduced into the new analogues.  
 
2.3 Manassantin B Scaffold 
 
During the course of this project, about 200 compounds have been synthesized by 
our group. This library consists purely of sulfonamide analogues and only about 20% 
of the compounds in the library were active. In the hopes of finding a much more 
potent candidate of HIF-1 inhibitors, new scaffolds were being investigated as a 
potential HIF-1 inhibitors.  
Manassantin B, a natural product that is extracted from the plant Saururus cernuus 
(common name: lizard’s tail) along with another extract, 4-O-demethylmanassantin 
have been discovered to affect the HIF-1 complex and inhibit its activity with IC50 
values in the range of 3 and 30 nM respectively.19 
 
Figure 8 Molecular structure of Manassantin B 
 
Manassantin B and 4-O-demethylmanassantin only differ by one methoxy group on 
the right hand side of the molecule; however, studies show that this slight change 
gives Manassantin B a tenfold increase in its potency in inhibiting the HIF-1 
activity.19 
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With this knowledge in hand, the synthesis of analogues that followed this scaffold 
commenced. The structure of Manassantin B is very complex; it would have been 
very tedious if synthesis of a very similar analogue were to be done solely for trial 
purposes. If the structure were taken into consideration, there is a relative similarity 
between the left side and the right side of the molecule that is only separated by a 
furan ring. Therefore, it was decided to direct the synthesis of analogues towards 
creating compounds that looked similar to one side of the natural product.  
 
Figure 9 Simplified structure of scaffold based on Manassantin B 
 
2.3.1 Chemistry of Manassantin B-like analogues 
 
 
Looking at the general structure shown in Figure 9, there are three structural groups 
that are important in this scaffold: the left core, the right core, and the 
hydroxymethine moiety. Different substitutions can be made with both left and right 
cores to see if they affect the HIF-1 complex as effectively as the natural product. 
The chemistry of these analogues usually starts with the preparation of both aryl 
groups (left and right core) separately before combining them (Equation 5). One of 
the aryl groups is usually prepared as a substituted aryl bromide and the other aryl 
group is usually prepared as a substituted aryl aldehyde. These two groups are 
condensed using n-butyllithium under an inert atmosphere at -78oC as seen in 
Equation 5.   
 
OH
R1 R2
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Equation 5 Condensation of the two cores for Manassantin-B derived analogues. R1 and R2 groups are 
listed in Figure 10 
 
 
 
2.4 Biological testing of analogues 
 
After the synthesis of the HIF-1 inhibitors, our collaborators at the Van Meir 
laboratory performed the biological testing of the analogues to investigate their HIF-
1-inhibiting activity. Using the plasmid construct with the six copies of the HRE of the 
VEGF gene that are upstream of a luciferase reporter gene, the IC50 of each 
analogue was reported using a concentration curve at 0, 1, 2, 3 and 5 µM with SR- 
IV-64b (Fig. 4) as a standard to compare the IC50 values to. In the results section of 
this study, any analogue that showed activity beyond 5 µM were not further tested 
and was designated to have activities >5 µM. These compounds’ activities were not 
further evaluated and thus their exact inhibiting activity, or lack thereof, was 
unknown.  Furthermore, the IC50 value of SR-IV-64b was not constant and had a 
range of 0.28 ± 0.12 µM in various experiments.  
 
3. RESULTS AND DISCUSSION 
3.1 Sulfonamide Analogues 
 
Using the SAR profile that was generated from previous studies, a couple of new 
analogues were synthesized. The main variation that was done on these analogues 
Br
R1 n-BuLi
OHC
R2
OH
R2R1
dry THF, -78oC
(5)
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targeted the nitrogen linker and the right hand core. The left hand core kept the 2,2-
dimethylbenzopyran group and the sulfonamide group was also retained. Below is 
the table of the sulfonamide analogues synthesized with their corresponding IC50 
and calculated LogP values which is the partition coefficient between hydrophobic 
and hydrophilic media.b,20 
 
Table 3 List of sulfonamide analogues synthesized with the 2,2-dimethylbenzopyran moiety kept intact 
 
 
                                                
b All LogP values were calculated using a virtual computational chemistry program. (VCCLAB, Virtual 
Computational Chemistry Laboratory, http://www.vcclab.org, 2005.) 
Compound Structure Mol. Wt. (g/mol) cLogP IC50 (µM) 
3 
 
489.12 3.74 >5 
4 
 
467.14 3.80 >5 
5 
 
402.51 2.51 >5 
6 
 
441.12 2.92 >5 
7 
 
419.14 3.24 >5 
8 
 
430.14 2.48 >5 
9 
 
427.18 3.22 4.37 
O
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With the series of compounds synthesized and comparing it to KCN-1 and SRIV-
64b, it can be seen that there was a decrease in biological activity once the right 
hand core was changed. Thus, it can be generalized that the dimethoxy group on 
both the para and meta positions of the aromatic ring on the sulfonamide analogues 
are necessary for biological activity. Of all the analogues that were synthesized in 
this class, only compound 9 was seen to remotely inhibit the activity of the HIF-1 
complex. This also proves that the dimethoxy group on the right hand is arguably a 
required group for biological inhibition since compound 9 is the only compound in the 
group that remotely resembles the active analogue (Figure 4). Furthermore, it can 
also be noted that although almost all analogues synthesized were inactive, all of 
them had cLogP values that were less than five, which is considered to be the upper 
limit of desired lipophilicity based on Lipinski’s Rule of Five that was used throughout 
this study.   
 
3.1.1 Morpholine group introduction 
 
Another approach that was taken during this study was the introduction of other ring 
structures into the sulfonamide group. For this particular study, we were hoping that 
the introduction of the morpholine group into our compounds would improve the 
analogues’ aqueous solubility while maintaining potency without introducing any 
further cellular toxicity. The chemistry of the analogues synthesized with this group 
followed the same procedures that were mentioned previously. This procedure used 
4-morpholinylbenzaldehyde as a starting material rather than its chromene 
counterpart (Scheme 1). The morpholine moiety was both introduced into the left 
hand core of the scaffold as well as the nitrogen linkers. The analogues were 
18 
 
subjected to same biological testing, and their IC50 values were measured and LogP 
calculated.  
 
Table 4 List of sulfonamide analogues synthesized with morpholine groups 
Compound Structure Mol. Wt. cLogP IC50 (µM) 
10 
 
448.20 3.51 1.23 
11 
 
418.19 3.41 >5 
12 
 
413.18 2.97 >5 
13 
 
446.19 3.33 2.62 
14 
 
502.21 3.13 >5 
15 
 
516.23 3.50 >5 
 
 
Looking at Table 4, the first change that was made was to introduce the morpholine 
ring into the left hand core of the scaffold. This was done in conjunction with the 
nitrogen linker having either a cyclobutyl or n-butyl substituent on the nitrogen atom 
(compounds 10-13). From this set, it can be seen that although the calculated LogP 
is comparably the same with the first set of sulfonamides synthesized, this set of 
analogues were relatively more active. This biological activity was perhaps caused 
by the combination of the morpholine group in tandem with an aliphatic nitrogen 
N S
O2
OMe
OMe
N
O
N S
O2
N
O
OMe
N S
O2
N
O
CN
N S
O2
N
O
OMe
OMe
O
N S
O2
OMe
N
O
OMe
O
N S
O2
OMe
OMe
N
O
19 
 
linker. The next change that was made in the scaffold was to introduce the 
morpholine group into the nitrogen linker and keep the 2,2-dimethylbenzopyran and 
dimethoxybenzyl group with the right hand and left hand core. As seen in Table 4, by 
introducing the morpholine group, there was not much difference that was seen in 
solubility; however, it is notable that compounds 14 and 15 lost their activities when 
the morpholine group was introduced. As it was previously mentioned that the 
dimethoxy group was necessary for biological activity; therefore, the morpholine 
group was not introduced into the right hand core.  
 
3.2 Manassantin-B derived Analogues 
 
For the synthesis of Manassantin B-derived analogues, the focus of variation was 
first directed towards the right hand side of the molecule as can be seen in the two 
compounds that were synthesized in Table 5.  These compounds contain a thioether 
ring that replaced the normal benzopyran group. This was done to diversify the 
compounds that were already synthesized. The synthesis of such compounds was 
done using the procedure described below.  
 
Scheme 2 Reaction procedure to synthesize the aryl-sulfane and thiophene moieties 
 
 
 
 
S
ClBr
N,N-dimethylaniline
170oC, 12h
S
Br
17
(7)
S
ClBrBr
SH
Cl Cl
K2CO3,
KI, CuI
acetone, 
55oC to r.t.
6h 16
(6)
20 
 
Table 5 Two analogues that were synthesized that followed the new scaffold 
Compound Structure Mol. Wt. cLogP IC50 (µM) 
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314.10 4.18 1.03 
19 
 
314.10 4.11 >5 
 
Looking at compounds 18 and 19, one important observation can be made. The 
structural difference between Manassantin B and 4-O-demethylmanassantin was 
only one methoxy group at the meta position of Manassantin B. This difference gave 
a tenfold increase in potency to the said molecule. Reviewing the compounds in 
Table 5, it can be seen that even if the structure did not mirror the natural product, it 
is still very obvious that the compound lost its biological activity once the methoxy 
group on the meta position of the aryl was eliminated. This experiment gives a good 
starting point for the SAR profile on the right core since it proves how necessary the 
dimethoxy moiety is. 
 
3.2.1 Importance of Hydroxymethine in the Scaffold 
 
Variation was also done on this new scaffold by changing the hydroxymethine group 
of the molecule. The efforts to change the group on the left hand side of the 
molecule have been substantial and our group has developed analogues that have 
very promising IC50 values. Therefore, for this particular study, it was decided to shift 
the focus to the hydroxymethine group and to observe its activity once it was 
changed based off of analogues that were previously synthesized. Five analogues 
whose variation was mainly focused on the left hand ring were chosen to see if their 
activity would change once the hydroxymethine group was varied. With this scaffold, 
S
OH
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S
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only the hydroxymethine group was changed and the right core of the analogues 
contained the dimethoxy groups in the para and meta positions of the aromatic ring. 
These five analogues were chosen as base compounds since they were either active 
as sulfonamide or as Manassantin B-like compounds. By oxidizing the hydroxy group 
into ketones using pyridinium chlorochromate, their activities were observed to see if 
any changes in the hydroxymethine group were significant enough in the gain or loss 
of biological inhibition.  
 
Figure 10 Functionalities of the five precursors chosen for hydroxymethine variation. These precursors 
were then reacted with either the 4-bromobenzene or 4-bromobenzaldehyde to produce their 
hydroxymethine compounds. 
 
The oxidation of the hydroxymethine group into its ketone counterpart was done 
using PCC oxidation and is described in Equation 8.  
 
 
 
 
Moreover, the hydroxymethine compounds that were used to synthesize the ketone 
products are listed below.  
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Figure 11 List of hydroxymethine compounds used to make the ketone products. 
In Figure 11, the figures for the five analogues whose left core was varied are drawn. 
The summary of their activities and their respective cLogP values are listed in Table 
6.  
Table 6 Biological results for the ketone analogues 
Compound Structure Mol. Wt.  cLogP IC50 (µM) 
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324.14 4.36 >5 
30 
 
325.36 3.49 >5 
31 
 
455.23 4.05 4.50 
32 
 
455.23 4.02 >5 
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33 
 
327.15 3.06 >5 
 
 
As seen in Table 6 and the comparison that was made in Table 7 below, it is obvious 
that the hydroxyl group on the hydroxymethine carbon proved to be highly important 
since its elimination led to a complete depletion of HIF-1 activity, as clearly seen in 
the case of the most potent compound in the list, compound 32. This result gives a 
clear view of what future directions to take and focus can be directed on the left core 
of the molecule.  
 
Table 7 Comparison of the data obtained for the hydroxymethine and ketone analogues 
Compound IC50 (µM) cLogP Compound 
IC50 
(µM) cLogP 
 
>5 4.23 
 
>5 4.36 
 
2.25 3.47 
 
>5 3.49 
 
0.89 3.55 
 
4.50 4.05 
 
0.20 3.52 
 
>5 4.02 
 
>5 2.63 
 
>5 3.06 
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3.2.2 Miscellaneous Compounds 
 
In the hopes of further diversifying the library of the new scaffold, two compounds 
were made to test synthetic procedures that would mimic the reactions that were 
planned for the ketone moieties synthesized. The carbonyl group of the ketones 
synthesized was reacted with hydroxylamine and hydrazine to form the oxime and 
hydrazone groups respectively. These compounds, albeit slightly different from the 
original scaffold, were submitted for biological testing to observe their activity. The 
compounds are listed in Table 7 and their respective reaction procedures can be 
seen below.  
 
 
 
Scheme 3 Reaction procedures for the synthesis of the miscellaneous compounds 
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Table 8 Miscellaneous compounds synthesized for synthetic purposes 
Compound Structure Mol. Wt. cLogP IC50 (µM) 
34 
 
257.11 3.19 >5 
35 
 
377.14 5.31 >5 
 
 
The two compounds that are seen in Table 7 were found to be inactive towards HIF-
1 inhibition. However, the synthetic procedures that were used to make such 
compounds were successful and can be used to create new analogues that contain 
the oxime and hydrazone moieties.  
 
4. Conclusion and Future Direction 
 
Cancer has been plaguing humanity since the earliest records of medicine were 
made. Although medical advances have contributed immensely to the search for a 
good therapy to cure cancer, it is still a challenge for scientists to improve treatments 
by decreasing the therapies’ side effects while increase potency. The HIF-1 complex 
is a very attractive target for cancer therapy because of its role in tumor biology. Its 
role as an angiogenetic promoter, among other things, can be exploited to create 
small molecules that would inhibit a tumor’s function and thereby inhibiting 
progression of cancer cells. In this study, a total of 22 compounds were synthesized 
that fell on three different classes of compounds. Most of the compounds that were 
synthesized in this study included sulfonamide analogues that give further diversity 
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with to the previously created library and will further elucidate the SAR profile of the 
sulfonamide class of HIF-1 inhibitors we have studied thus far. Some compounds 
were also synthesized that were based off of Manassantin B and have given us a 
new scaffold to investigate for HIF-1 inhibition. The last class of compounds that was 
synthesized were analogues of a potent Manassantin B-derived compound 
previously synthesized by other members of our group. These compounds proved 
that the hydroxymethine group in this particular scaffold holds great importance since 
its elimination leads to loss of inhibition. In the future, the observations made through 
this study will help in the synthesis of new and more potent HIF-1 inhibitors. 
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Experimental: 
 
All starting materials were obtained from Sigma-Aldrich, Acros Organics or Oakwood 
Chemicals and were used without further purification. Microwave heating was 
performed in a single-mode microwave cavity of a Discovery Synthesis System 
(CEM corp.) and the microwave-irradiated reactions were conducted in a heavy-
walled glass vials sealed with Teflon septa. 1H and 13C NMR spectra were recorded 
at 400 MHz and 100 MHz, respectively, on a Bruker Avance 400 NMR spectrometer 
using CDCl3 containing tetramethylsilane (TMS) an internal calibration standard. 
Mass spectra analyses were performed by the mass spectrometry facilities at 
Georgia State University.  
 
Procedures: 
I. Sulfonamide analogues 
 
 
4-((2-Methylbut-3-yn-2-yl)oxy)benzaldehyde  (1) 
In a 100 mL round bottom flask, 2 g (0.015 mol) of p-hydroxybenzaldehyde was 
dissolved in dry acetonitrile (10 mL) and was cooled to 0 oC under inert atmosphere 
with argon gas. To this solution, 9.0 mL (0.06 mol) of DBU was added and the 
solution was allowed to stir for 30 min. 6.8 mL (0.06 mol) of 3-chloro-3-methylbut-1-
yne was then added into the mixture drop wise. The solution was allowed to warm up 
to room temperature and was stirred overnight. The solution was concentrated and 
extracted with ethyl acetate (100 mL). The organic solution was washed with 1M HCl 
O
OHC
30 
 
solution (20 mL), 1M NaOH solution (20 mL), saturated NaHCO3 solution (20 mL), 
and brine (20 mL) and was dried over Na2SO4. The organic layer was concentrated 
in vacuo and was taken directly to the next step.  
 
2,2-Dimethyl-2H-chromene-6-carbaldehyde (2) 
Using the impure product from the procedure above, the crude mixture was 
dissolved in N,N-dimethylaniline (<1 mL) and heated at 170 oC for 6 h. After cooling 
to room temperature, the organic layer was extracted with ethyl acetate (20 mL), and 
washed with IM HCl (20 mL x 3), saturated NaHCO3 solution (20 mL), and brine 20 
mL), and was dried over Na2SO4. The organic layer was concentrated in vacuo. The 
product was purified using flash column chromatography. Ethyl acetate and hexanes 
were used as eluent (1:8). Yield: 2 g, 37%. 1H NMR (400 MHz, CDCl3): δ 9.61 (s, 
1H), 7.42 (d, J = 8.0 Hz, 1H), 7.28 (s, 1H), 6.64 (d, J = 8.0 Hz, 1H), 6.14 (d, J = 8.0 
Hz, 1H), 5.47 (d, J = 8.0 Hz, 1H), 1.24 (s, 6H) ppm. 13C NMR: δ 190.2, 158.3, 131.5, 
131.3, 129.9, 127.7, 121.2, 121.0, 116.7 and 28.24 ppm.  
 
General procedure for the reductive amination of 2,2-dimethyl-2H-chromene-6-
carbaldehyde: 
 
To a solution of 100 mg of aldehyde (1 eq.) and 21 mg of InCl3 (0.15 eq.) in dry 
MeOH (10 mL) under Argon gas, the corresponding amount of amine (1.5 eq.) was 
added. The mixture was allowed to stir until completion as monitored by TLC. Upon 
consumption of the aldehyde, 36 mg of NaCNBH4 (1.5 eq.) was added and was 
allowed to stir for 1 h. The reaction mixture was quenched with saturated 10 mL of 
O
OHC
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NH4Cl solution. The organic layer was extracted with ethyl acetate (20 mL), washed 
with brine (20 mL) and dried over Na2SO4. The product was taken to the next step 
without further purification.  
 
General procedure for sulfonylation reactions of the secondary amine:  
 
In a 50 mL round-bottom flask, 50 mg of the crude secondary amine (1 eq.) in DCM 
(10 mL) was added the corresponding amounts of K2CO3 (2 eq.), then appropriate 
amounts of the sulfonyl chloride moiety (2 eq.). The reaction mixture was stirred at 
room temperature for 24 h. The solution was then washed with deionized water (10 
mL) and the organic layer was extracted with DCM (10 mL x 2), washed with brine 
(20 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified using flash column chromatography. Ethyl acetate and hexanes were used 
as eluent (1:8). 
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-N-phenyl-4-
(trifluoromethoxy)benzenesulfonamide (3) – Yield: 18 mg, 18%. 1H NMR: δ 8.13-
8.11 (d, J = 8.8 Hz, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.8 Hz, 1H), 7.30 (d, J 
= 8.0 Hz, 2H), 7.23-7.22 (m, 2H), 6.96 (d, J = 3.2 Hz, 2H), 6.86 (d, J = 8.8 Hz, 1H), 
6.59 (d, J = 8.0 Hz, 1H), 6.22 (d, J = 10.0 Hz, 1H), 5.57 (d, J = 10.0 Hz, 1H), 4.63 (s, 
2H), 1.38 (s, 6H) ppm. 13C NMR: δ 138.6, 137.3, 131.0, 129.8, 129.5, 129.4, 129.1, 
129.0, 128.1, 127.7, 126.7, 122.0, 121.2, 121.1, 120.6, 116.1, 54.6, 28.0 ppm. 
HRMS (ESI) m/z calculated for C25H22F3NO4S + Na+: 512.1119, found 512.1106.  
O
N S
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N-Cyclobutyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-4-
(trifluoromethoxy)benzenesulfonamide (4) – Yield: 66 mg, 48%. 1H NMR: δ 7.82 
(d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 1H), 6.96 (s, 1H), 
6.72 (d, J = 8.0 Hz, 1H), 6.30 (d, J = 9.6 Hz, 1H), 5.63 (d, J = 9.6 Hz, 1H), 4.33 (s, 
2H), 4.26-4.18 (m, 1H), 2.03-1.99 (m, 4H), 1.58 (m, 2H), 1.44 (s, 6H) ppm. 13C NMR: 
δ 152.3, 151.9, 139.0, 131.1, 129.9, 129.1, 127.9, 125.3, 122.2, 121.3, 120.8, 116.2, 
52.9, 48.2, 29.3, 28.0, 15.0 ppm. HRMS (ESI) m/z calculated for C23H24NO4F3S + 
Na+: 490.1276, found 490.1278.  
 
N-Cyclobutyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3,5-dimethylisoxazole-
4-sulfonamide (5) - Yield: 47 mg, 43%. 1H NMR: δ 7.02 (d, J = 8.4 Hz, 1H), 6.91 (s, 
1H), 6.72 (d, J = 8.4 Hz, 1H), 6.31-6.28 (d, J = 10.0 Hz, 1H), 5.65-5.62 (d, J = 10.0 
Hz, 1H), 4.41 (s, 2H), 4.28-4.10 (m, 1H), 2.58 (s, 3H), 2.39 (s, 3H) 2.09-2.04 (m, 4H), 
1.62-1.52 (m, 2H) 1.43 (s, 6H) ppm. 13C NMR: δ 172.7, 157.3, 152.4, 131.3, 129.5, 
127.8, 125.2, 122.1, 121.4, 117.5, 116.3, 52.2, 47.8, 29.3, 27.9, 15.0, 12.8, 11.1 
ppm. HRMS (ESI) m/z calculated for C21H26N2O4S + Na+: 425.1511, found 425.1529.  
 
 
O
N S
O2
O CF3
O
N SO2
O N
33 
 
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-3,4-difluoro-N-
phenylbenzenesulfonamide (6) - Yield: 30 mg, 37%. 1H NMR: δ 7.50 (t, J = 8.8 Hz, 
1H), 7.43 (d, J = 8.4 Hz, 1H), 7.32-7.26 (m, 4H), 6.98-6.96 (m, 2H), 6.89 (d, J = 10.8 
Hz, 2H), 6.62 (d, J = 10.0 Hz, 1H), 6.24 (d, J = 10.0 Hz, 1H), 5.59 (d, J = 10.0 Hz, 
1H), 4.65 (s, 2H), 1.41 (s, 6H) ppm. 13C NMR: δ 152.6, 138.4, 131.0, 129.4, 129.1, 
129.0, 128.3, 127.6, 126.7, 122.0, 121.2, 118.0, 117.8, 116.2 ppm. HRMS (ESI) m/z 
calculated for C24H21NO3F2S + Na+: 464.1108, found 464.1097.  
 
N-Cyclobutyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3,4-
difluorobenzenesulfonamide (7) –Yield: 37 mg,  29%. 1H NMR: δ 7.61-54 (m, 2H), 
7.29-7.28 (m, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.96 (s, 1H), 6.72 (d, J = 8.0 Hz, 1H), 
6.30 (d, J = 9.6 Hz, 1H), 5.64 (d, J = 9.6 Hz, 1H), 4.32 (s, 2H), 4.23-4.19 (m, 1H), 
2.06-1.99 (m, 4H), 1.55-1.52 (m, 2H), 1.44 (s, 6H) ppm. 13C NMR: δ 152.4, 148.9, 
137.4, 131.1, 129.7, 128.0, 125.3, 122.1, 121.3, 118.1, 117.9, 117.0, 116.8, 116.3, 
52.8, 48.2, 29.3, 28.0, 15.0 ppm. HRMS (ESI) m/z calculated for C22H23NO3F2S + 
Na+: 442.1264, found 442.1255.  
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4-Cyano-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-
phenylbenzenesulfonamide (8) –Yield: 15 mg, 30%. 1H NMR: δ 7.77 (q, J = 8.4 
Hz, 4H), 7.27 (t, J = 5.2, 3H), 6.95-6.93 (m, 2H), 6.89-6.85 (m, 2H), 6.62 (d, J = 8.0 
Hz, 1H), 6.23 (d, J = 10.0 Hz, 1H), 5.60 (d, J = 10.0 Hz, 1H), 4.66 (s, 2H), 1.41 (s, 
6H) ppm. 13C NMR: δ 152.7, 143.2, 138.2, 132.7, 131.1, 129.5, 129.2, 129.1, 128.4, 
128.2, 127.3, 126.7, 122.0, 121.2, 116.3, 116.2, 54.9, 28.0 ppm. HRMS (ESI) m/z 
calculated for C25H22N2O3S + Na+: 453.1249, found 453.1260.  
 
N-Cyclobutyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-4-
ethoxybenzenesulfonamide (9) – Yield: 16 mg, 36%. 1H NMR: δ 7.69 (d, J = 8.0 
Hz, 2H), 7.04 (d, J = 8.4 Hz, 1H), 6.98 (s, 1H), 6.93 (d, J = 8.8 Hz, 2H), 6.70 (d, J = 
8.0 Hz, 1H), 6.29 (d, J = 10.0 Hz, 1H), 5.60 (d, J = 10.0 Hz, 1H), 4.26 (s, 2H), 4.18-
4.10 (m, 1H), 4.10-4.05 (m, 2H), 2.00-1.90 (m, 4H), 1.52-1.44 (m, 5H), 1.42 (s, 6H) 
ppm. 13C NMR: δ 162.1, 152.1, 131.8, 130.9, 130.7, 129.1, 127.9, 125.3, 122.4, 
121.2, 116.1, 114.5, 63.9, 52.9, 48.2, 29.2, 28.0, 15.1, 14.6 ppm. HRMS (ESI) m/z 
calculated for C24H29O4NS + Na+: 450.1710, found 450.1709.  
 
N-Butyl-3,4-dimethoxy-N-(4-morpholinobenzyl)benzenesulfonamide (10) – 
Yield: 10 mg, 23%. 1H NMR: δ 7.47 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 5.2 Hz, 2H), 7.18 
(d, J = 8.0 Hz, 2H), 6.95 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 4.26 (s, 2H), 
3.97 (s, 3H), 3.92 (s, 3H), 3.87 (t, J = 4.4. Hz, 4H), 3.16 (t, J = 9.2 Hz, 4H), 3.09 (t, J 
= 7.6 Hz, 2H), 1.39-1.34 (m, 2H), 1.32-26 (m, 2H), 1.18 (t, J = 7.2 Hz, 3H) ppm. 13C 
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NMR: δ 152.3, 149.0, 132.2, 129.4, 121.0, 115.5, 110.6, 110.0, 66.9, 56.2, 51.0, 
49.3, 47.3, 29.9, 19.9, 13.6 ppm. HRMS (ESI) m/z calculated for C23H33N2O5S [(M + 
H)+]: 449.2110, found 449.2094. 
 
N-Butyl-4-methoxy-N-(4-morpholinobenzyl)benzenesulfonamide (11) – Yield: 48 
mg, 36%. 1H NMR: δ 7.76 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 
8.8 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 4.23 (s, 2H), 3.87-3.85 (m, 4H), 3.84 (s, 3H), 
3.15-3.13 (m, 4H), 3.04 (t, J = 7.6 Hz, 2H), 1.35-1.27 (m, 2H), 1.17-1.09 (m, 2H), 
0.76-0.72 (t, J = 7.2 Hz, 3H) ppm. 13C NMR: δ 162.6, 132.1, 129.4, 129.2, 115.6, 
114.2, 66.9, 55.6, 51.1, 49.3, 47.3, 30.0, 19.9, 13.6 ppm. HRMS (ESI) m/z calculated 
for C22H31O4N2S [(M + H)+]: 419.1999, found 419.1980.  
 
N-Butyl-4-cyano-N-(4-morpholinobenzyl)benzenesulfonamide (12) – Yield: 21 
mg, 33%. 1H NMR: δ 7.92 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 8.4, 2H), 7.12 (d, J = 8.4 
Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 4.31 (s, 2H), 3.89-3.86 (m, 4H), 3.17-3.11 (m, 6H), 
1.38-1.34 (m, 2H), 1.19-1.13 (m, 2H), 0.80 (t, J = 7.2 Hz, 3H) ppm. 13C NMR: δ 
151.1, 144.9, 132.8, 139.4, 137.6, 126.5, 117.5, 115.9, 115.4, 66.8, 50.9, 49.1, 47.4, 
29.9, 19.7, 13.6 ppm. HRMS (ESI) m/z calculated for C22H28O3N3S [(M + H)+]: 
414.1846, found 414.1857.  
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N-Cyclobutyl-3,4-dimethoxy-N-(4-morpholinobenzyl)benzenesulfonamide (13) – 
Yield: 81 mg, 70%. 1H NMR: δ 7.39 (d, J = 8.4 Hz, 1H), 7.28-7.20 (m, 3H), 6.91 (d, J 
= 8.4 Hz, 1H), 6.85 (d, J = 8.4, 2H), 4.32 (s, 2H), 4.24-4.18 (m, 1H), 3.93 (s, 3H), 
3.88 (s, 3H), 3.86 (m, 4H), 3.15 (m, 4H), 2.02-1.89 (m, 4H), 2.05-1.90 (m, 4H), 1.55-
1.25 (m, 2H) ppm. 13C NMR: δ 152.3, 150.5, 149.0 132.2, 129.8, 128.2, 120.9, 
115.6, 110.6, 109.7, 66.9, 56.2, 56.1, 52.9, 49.4, 48.0, 29.7, 29.3, 15.1 ppm. HRMS 
(ESI) m/z calculated for C23H31O5N2S [(M + H)+]: 446.1948, found 447.1949.  
 
N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-3,4-dimethoxy-N-(2-
morpholinoethyl)benzenesulfonamide (14) – Yield: 31 mg, 49%. 1H NMR: δ 7.45 
(d, J = 8.4 Hz, 1H), 6.93 (t, J = 9.6 Hz, 2H), 6.85 (s, 1H), 6.67 (d, J = 8.4 Hz, 1H), 
6.22 (d, J = 10.0 Hz, 1H), 5.58 (d, J = 10.0 Hz, 1H), 4.23 (s, 2H), 3.93 (s, 3H), 3.89 
(s, 3H), 3.59 (s, 4H), 3.19 (t, J = 7.2 Hz, 2H), 2.32 (t, J = 7.2 Hz, 2H), 2.26 (s, 4H), 
1.96 (s, 6H) ppm. 13C NMR: δ 152.7, 152.5, 149.1, 131.8, 131.3, 129.1, 128.3, 
126.5, 122.0, 121.4, 121.9, 116.3, 110.6, 109.8, 66.8, 57.3, 56.3, 56.2, 53.6, 52.2, 
44.4, 27.9 ppm. HRMS (ESI) m/z calculated for C26H35O6N2S [(M + H)+]: 503.2210, 
found 503.2204.  
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N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-3,4-dimethoxy-N-(3-
morpholinopropyl)benzenesulfonamide (15) – Yield: 16 mg, 14%. 1H NMR: δ 
7.43 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 6.98-6.93 (m, 2H), 6.87 (s, 1H), 6.68 (d, J = 8.4 
Hz, 1H), 6.23 (d, J = 10.0 Hz, 1H), 5.60 (d, J = 10 Hz, 1H), 4.19 (s, 2H), 3.94 (s, 3H), 
3.91 (s, 3H), 3.60 (s, 4H), 3.12 (t, J = 7.6 Hz, 2H), 2.22 (s, 4H), 2.18 (t, J = 8.0 Hz, 
2H), 1.59-1.52 (m, 2H), 1.40 (s, 6H) ppm. 13C NMR: δ 152.8, 152.4, 149.1, 131.6, 
131.3, 129.3, 128.4, 126.5, 121.9, 121.3, 121.0, 116.3, 110.6, 109.8, 66.9, 56.3, 
55.9, 53.4, 52.0, 46.2, 28.0, 25.4 ppm. HRMS (ESI) m/z calculated for C27H37O6N2S 
[(M + H)+]: 517.2367, found 517.2366.  
 
II. Hydroxymethine analogues 
 
 
(4-bromophenyl)(2-chloroallyl)sulfane (16) 
In a 50 mL three-neck round bottom flask, 100 mg (1 eq.) of 4-bromothiophenol, 146 
mg of K2CO3 (2 eq.), 150 mg (1.7 eq) of KI and 5 mg (0.05 eq) of CuI were mixed in 
acetone (10 mL) and was put under argon gas. The solution was then heated up to 
55oC for 15 min and 106 mg (1.8 eq) of 2,3-dichloroprop-1-ene was added. The 
reaction mixture stirred for 6 h and was allowed to cool down to room temperature. 
The mixture was treated with DI H2O (20 mL) and diethyl ether (20 mL). The ethereal 
layer was washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo. 
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The product was purified using flash column chromatography. Hexanes were used 
as eluent. Yield: 46 mg, 33%. 1H NMR: δ 7.44 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 8.4 
Hz, 2H), 5.27 (s, 2H), 3.70 (s, 2H). 13C NMR: δ 137.5, 133.8, 132.6, 132.1, 121.3, 
115.1, 42.8 ppm.  
 
5-bromo-2-methylbenzo[b]thiophene (17) 
In a 50 mL round bottom flask, the sulfane product was treated with <1 mL of N,N-
dimethylaniline and was stirred at 170oC for 12 h. The solution was taken up in ethyl 
acetate (20 mL), washed with IM HCl (20 mL x 3), saturated NaHCO3 solution (20 
mL), brine 20 mL) and was dried over Na2SO4. The organic layer was concentrated 
in vacuo. The product was purified using flash column chromatography. Hexanes 
were used as eluent (1:8). Yield: 19 mg, 48%. 1H NMR: δ 7.77 (d, J = 1.2 Hz, 1H), 
7.59 (d, J = 8.8 Hz, 1H), 7.34 (dd, J = 8.8 Hz, 1.6 Hz, 1H), 6.90 (s, 1H), 2.59 (s, 3H) 
ppm. 13C NMR: δ 132.2, 129.4, 126.3, 125.2, 123.3, 120.9, 16.2 ppm.   
 
2-Bromo-5-((2-methylbut-3-yn-2-yl)oxy)pyridine (20a) 
In a 100 mL round bottom flask, 2 g (0.012 mol) of 6-bromopyridin-3-ol was 
dissolved in dry acetonitrile (10 mL) and was cooled to 0oC under Argon gas. To this 
solution, 9.0 mL (0.05 mol) of DBU was added and the solution was allowed to stir 
for 30 min. 6.8 mL (0.05 mol) of 3-chloro-3-methylbut-1-yne was then added into the 
mixture drop wise. The solution was allowed to warm up to room temperature and 
was stirred overnight. The solution was concentrated and was taken up with ethyl 
acetate (100 mL). The organic solution was washed with 1M HCl solution (20 mL), 
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1M NaOH solution (20 mL), saturated NaHCO3 solution (20 mL), brine (20 mL) and 
was dried over Na2SO4. The organic layer was concentrated in vacuo and was taken 
directly to the next step.  
 
6-Bromo-2,2-dimethyl-2H-pyrano[3,2-b]pyridine (20) 
Using the impure product from the procedure above, the crude mixture was 
dissolved in N,N-dimethylaniline (<1 mL) at 170oC for 6 h. The solution was taken up 
in ethyl acetate (20 mL), washed with IM HCl (20 mL x 3), saturated NaHCO3 
solution (20 mL), brine 20 mL) and was dried over Na2SO4. The organic layer was 
concentrated in vacuo. The product was purified using flash column 
chromatography. Hexanes were used as eluent.  Yield: 239.4 mg, 34%. 1H NMR: δ 
7.10 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.40 (d, J = 10.0 Hz, 1H), 5.83 (d, J 
= 10.0 Hz, 1H), 1.41 (s, 6H) ppm. 13C NMR: δ 149.1, 142.1, 136.0, 131.3, 127.4, 
125.9, 123.0, 28.2 ppm. 
 
Tert-butyl 4-((4-bromobenzyl)oxy)piperidine-1-carboxylate (21) 
In a 100 mL round bottom flask, 2 g (0.012 mol) of tert-butyl 4-hydroxypiperidine-1-
carboxylate and 295 mg (0.8 mmol) of TBAI  was dissolved in dry THF (10 mL) and 
was cooled to 0oC under inert atmosphere with Argon gas. To this solution, 480 mg 
(0.02 mol) of NaH was added and the solution was allowed to stir for 30 min. 2.4 g 
(0.008 mol) of 4-bromobenzyl bromide was then added into the mixture. The solution 
was allowed to warm up to room temperature and was stirred overnight. The solution 
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was quenched with saturated NH4Cl solution (20 mL) and the organic layer was 
extracted up with ethyl acetate (50 mL), washed with brine (20 mL) and was dried 
over Na2SO4. The organic layer was concentrated in vacuo and was purified using 
flash column chromatography. Hexanes were used as eluent. Yield: 2 g, 64%. 1H 
NMR: δ 7.44 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 4.48 (s, 2H), 3.77-3.74 (m, 
2H), 3.55-3.51 (m, 1H), 3.12-3.06 (m, 2H), 1.82 (bs, 2H), 1.60-1.57 (m, 2H), 1.44 (s, 
9H) ppm. 13C NMR: δ 154.8, 137.9, 131.5, 129.1, 121.3, 79.5, 74.2, 69.1, 60.4, 41.0, 
34.7, 31.6, 31.0, 28.4, 25.3, 22.7, 21.0, 14.2, 14.1 ppm.  
 
Tert-butyl 4-((3-bromobenzyl)oxy)piperidine-1-carboxylate (22) 
In a 50 mL round bottom flask, 120 mg (0.60 mmol) of tert-butyl 4-hydroxypiperidine-
1-carboxylate and 15 mg (0.04 mmol) of TBAI  was dissolved in dry THF (10 mL) 
and was cooled to 0oC under inert atmosphere with Argon gas. To this solution, 24 
mg (1.0 mmol) of NaH was added and the solution was allowed to stir for 30 min. 
100 mg (0.40 mmol) of 4-bromobenzyl bromide was then added into the mixture. The 
solution was allowed to warm up to room temperature and was stirred overnight. The 
solution was quenched with saturated NH4Cl solution (20 mL) and the organic layer 
was extracted up with ethyl acetate (20 mL), washed with brine (20 mL) and was 
dried over Na2SO4. The organic layer was concentrated in vacuo and was purified 
using flash column chromatography. Hexanes were used as eluent.  Yield: 167 mg, 
75%. 1H NMR: δ 7.51(s, 1H), 7.42 (d, J = 6.4 Hz, 1H), 7.28-7.20 (m, 2H), 4.53-4.52 
(s, 2H), 3.79-3.78 (m, 2H), 3.57-3.55 (m, 1H), 3.14-3.10 (m, 2H), 1.86 (bs, 2H), 1.61-
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1.59 (m, 2H), 1.28 (s, 9H) ppm. 13C NMR: δ 154.8, 141.1, 130.6, 130.3, 130.0, 125.8 
122.6, 79.5, 74.4, 69.0, 31.0, 28.4 ppm.  
 
General procedure for the synthesis of hydroxymethine products: 
 
A flask of the aryl bromide (1 eq.) was degassed and anhydrous THF (10 mL) was 
added under nitrogen gas. The solution was cooled to -78oC and stirred for 1 h. n-
BuLi (0.9 eq) was then added to the solution drop wise. To this solution, the 
aldehyde (1.1 eq) was added dropwise and the reaction mixture was stirred for 1 h 
and was allowed to warm up to room temperature. The mixture was then quenched 
with saturated ammonium chloride solution (20 mL) and the organic layer was 
extracted with ethyl acetate (20 mL x 2), washed with brine (25 mL x 1), dried over 
Na2SO4 and concentrated in vacuo. The product was purified using flash column 
chromatography. Ethyl acetate and hexanes were used as eluent (1:3). 
 
(3,4-Dimethoxyphenyl)(2-methylbenzo[b]thiophen-5-yl)methanol (18) – Yield: 3 
mg, 12%. 1H NMR: δ 7.70 (s, 1H), 7.67 (d, J = 4.0 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 
6.94 (s, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 5.90 (s, 1H), 3.86 (s, 
3H), 3.84 (s, 3H), 2.58 (s, 3H) ppm, 2.20 (d, J = 2 Hz, 1H). HRMS (ESI) m/z 
calculated for C18H18O3S + Na+: 337.0874, found 337.0883. 
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(2,4-Dimethoxyphenyl)(2-methylbenzo[b]thiophen-5-yl)methanol (19) – Yield: 3 
mg, 14%. 1H NMR: δ 7.67 (d, J = 4.8 Hz, 2H), 7.24 (s, 1H), 7.07 (d, J = 4.0 Hz, 1H), 
6.94 (s, 1H), 6.47 (s, 1H), 6.44 (d, J = 8.4 Hz, 1H), 6.10 (d, J = 4.8 Hz, 1H), 3.80 (s, 
3H), 3.79 (s, 3H), 2.92 (d, J = 5.2 Hz, 1H), 2.57 (s, 3H) ppm. HRMS (ESI) m/z 
calculated for C18H18O3S + Na+: 337.0874, found 337.0863. 
  
(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-chromen-6-yl)methanol (24) - Yield: 104 
mg, 63%. 1H NMR: δ 7.09 (d, J = 8.0 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 1H), 6.90 (d, J = 
8.0 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 6.29 (d, J = 9.6 Hz, 
1H), 5.72 (s, 1H), 5.61 (d, J = 9.6 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 2.20 (s, 1H), 
1.43 (s, 6H) ppm. 13C NMR: δ 152.4, 149.0 148.4, 136.7, 136.3, 130.9, 127.4, 124.6, 
122.3, 121.1, 118.8, 116.2, 110.9, 109.7, 76.3, 75.5, 55.9, 55.9, 28.0, 28.0 ppm. 
HRMS (ESI) m/z calculated for C20H22O4 + Na+: 349.1416, found 349.1419. 
 
(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methanol (25) 
– Yield: 69 mg, 53%. 1H NMR: δ 6.95 (d, J = 8.0 Hz, 1H), 6.87 (d, J = 5.2 Hz, 2H), 
6.80 (d, J = 4.4 Hz, 2H), 6.79 (dd, J = 8.4, 4 Hz, 2H), 6.50, (d, J = 10.0 Hz, 1H) 5.85 
(d, J = 10.0 Hz, 1H), 5.58 (s, 1H), 5.14 (bs, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 1.43 (s, 
6H) ppm. 13C NMR: 152.8, 149.1, 148.7, 148.6, 139.2, 136.1, 135.3, 124.0, 123.6, 
121.1, 119.5, 119.3, 111.0,110.4, 74.4, 55.9, 55.8, 28.3 ppm. 
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Tert-butyl 4-((4-((3,4-dimethoxyphenyl)(hydroxy)methyl)benzyl)oxy)piperidine-
1-carboxylate (26) - Yield: 877 mg, 54%. 1H NMR: δ 7.35 (d, J = 8.0 Hz, 2H), 7.30 
(d, J = 8.4 Hz, 2H), 6.91 (d, J = 1.6 Hz, 1H), 6.88-6.86 (m, 1H), 6.80 (d, J = 8.4 Hz, 
1H), 5.78 (s, 1H), 4.52 (s, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.77-3.73 (m, 2H), 3.57-
3.51 (m, 1H), 3.11-3.05 (m, 2H), 2.39(s, 1H), 1.84-1.82(m, 2H), 1.58-1.55(m, 2H), 
1.44 (s, 9H) ppm. 13C NMR: δ 149.1, 143.3, 137.9, 136.6, 127.6, 126.5, 118.9, 
110.9, 109.7, 79.5, 75.8, 74.0, 69.6, 60.4, 55.9, 55.8, 28.4, 21.0, 14.2 ppm.  
 
Tert-butyl 4-((3-((3,4-dimethoxyphenyl)(hydroxy)methyl)benzyl)oxy)piperidine-
1-carboxylate (27) – Yield: 41 mg, 33%. 1H NMR: δ 7.74 (s, 1H), 7.66 (d, J = 7.6 Hz, 
1H), 7.57 (d, J = 7.2 Hz, 1H), 7.50-7.34 (m, 2H), 7.38 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 
8.4 Hz, 1H), 5.80 (s, 1H), 4.62 (s, 2H), 3.97 (s, 3H), 3.95 (s, 3H), 3.76 (bs, 2H), 3.60 
(m, 1H), 3.14-3.08 (m, 2H), 2.46 (s,1H), 1.85 (bs, 2H), 1.62 (bs, 2H), 1.48 (s, 9H) 
ppm.  13C NMR: δ 154.8, 149.0 148.4, 144.3, 138.8, 136.7, 128.5, 126.5, 125.7, 
125.5, 119.0, 110.9, 109.9, 79.5, 75.7, 74.1, 69.8, 55.9, 55.8, 41.2, 34.1, 31.0, 28.4 
ppm. 
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(3,4-Dimethoxyphenyl)(4-morpholinophenyl)methanol (28) - Yield: 167 mg, 55%. 
1H NMR: δ 7.25 (d, J = 8.0 Hz, 2H), 6.92 (s, 1H), 6.87-6.80 (m, 4H), 5.70 (s, 1H), 
3.85 (s, 3H), 3.83 (s, 3H), 3.82 (m, 4H), 3.12-3.10 (m, 4H), 2.80 (bs, 1H) ppm. 13C 
NMR: δ 150.6, 148.9, 148.2, 136.9, 135.7, 127.5, 118.8, 115.6, 110.8, 109.7, 75.4, 
66.8, 66.5, 55.9, 55.87, 49.3 ppm. HRMS (ESI) m/z calculated for C19H24NO4 [(M + 
H)+] 330.1705, found 330.1710. 
 
III. Ketone derivatives from  hydroxymethine products 
 
General procedure for the ketone products:  
 
To a solution of 50 mg of hydroxymethine product (1 eq.) in DCM (10 mL) was added 
Celite (33 mg Celite/ hydroxymethine product) as solid support. The reaction mixture 
was then charged with the appropriate amounts of PCC (2 eq) and was allowed to 
stir at room temperature for 24 h. The solution mixture was filtered and washed with 
DCM (20 mL x 3) and concentrated in vacuo. The crude product was purified using 
flash column chromatography. Ethyl acetate and hexanes were used as eluent 
(1:10). 
 
 
(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-chromen-6-yl)methanone (29) – Yield: 
77 mg, 74%. 1H NMR: δ 7.49 (d, J = 8.4 Hz, 1H), 7.41 (s, 1H), 7.34 (s, 1H), 7.28 (d, J 
= 8.4 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.26 (d, J = 10.0 Hz, 
1H), 5.58 (d, J = 10.0 Hz, 1H), 3.87(s, 3H), 3.85 (s, 3H), 1.39 (s, 6H) ppm. 13C NMR: 
O
O
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δ 194.3, 171.1, 156.7, 152.5, 149.0, 131.9, 131.2, 130.8, 130.7, 128.6, 124.7, 121.7, 
120.6, 115.8, 112.2, 109.7, 60.3, 56.1, 56.0, 28.4, 21.0, 14.2 ppm. HRMS (ESI) m/z 
calculated for C20H21O4 [(M + H)+]: 325.1440, found 325.1433.  
 
(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methanone 
(30) – Yield: 44 mg, 64%. 1H NMR: δ 7.87-7.83 (m, 2H), 7.79 (s, 1H), 7.15 (d J = 8.4 
Hz,1H), 6.92 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 10.0 Hz, 1H), 5.976 (d, J = 10.0 Hz, 
1H), 3.96 (s,3H), 3.95 (s, 3H), 1.53 (s, 6H) ppm. 13C NMR: δ 190.9, 153.0, 152.0, 
148.6, 147.7, 139.6, 135.7, 130.0, 126.6, 126.1, 123.8, 123.1, 113.3, 109.8, 78.2, 
56.1, 56.0, 28.7 ppm. HRMS (ESI) m/z calculated for C19H20O4N [(M + H)+]: 
326.1387, found 326.1392. 
 
Tert-butyl 4-((4-(3,4-dimethoxybenzoyl)benzyl)oxy)piperidine-1-carboxylate (31) 
– Yield: 594 mg, 68% 1H NMR: δ 7.69 (d, J = 8.4 Hz, 2H), 7.42-7.39 (m, 3H), 7.31 (d, 
J = 8.4 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 4.58 (s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 
3.75-3.72, (m, 2H), 3.56-3.54 (m, 1H), 3.10-3.04 (m, 2H), 1.96 (s, 1H), 1.82 (bs, 2H), 
1.59-1.53 (m, 2H), 1.40 (s, 9H) ppm. 13C NMR: δ 195.1, 171.0, 154.8, 153.0, 148.9, 
143.0, 137.4, 130.2, 130.0, 126.9, 125.4, 112.1, 109.8, 79.4, 74.5, 69.3, 60.3, 56.0, 
55.9, 41.1, 31.0, 28.4, 21.0, 14.2 ppm. HRMS (ESI) m/z calculated for C26H33O6N + 
Na+: 478.2200, found 478.2199. 
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Tert-butyl 4-((3-(3,4-dimethoxybenzoyl)benzyl)oxy)piperidine-1-carboxylate (32) 
– Yield: 16 mg, 54%. 1H NMR: δ 7.73 (s, 1H), 7.75 (d, J = 7.2 Hz, 1H), 7.56 (d, J = 
7.2 Hz, 1H), 7.49 (s, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.37 (dd, J = 8.4, 1.6 Hz, 1H), 6.88 
(d, J = 8.4, 1H), 4.61 (s, 2H), 3.96 (s, 3H), 3.94 (s, 3H), 3.76 (m, 2H), 3.61-3.57 (m, 
1H), 3.13-3.07 (m, 3H), 1.86 (bs, 2H), 1.66-1.58 (m, 2H), 1.45 (s, 9H) ppm. 13C 
NMR: δ 195.5, 154.5, 153.1, 149.0, 139.1, 138.4, 130.9, 130.2, 129.0, 128.6, 128.2, 
125.5, 112.1, 109.8, 79.5, 74.5, 69.5, 56.1, 56.0, 31.0, 28.4 ppm. HRMS (ESI) m/z 
calculated for C26H33O6N + Na+: 478.2200, found 478.2197. 
 
(3,4-Dimethoxyphenyl)(4-morpholinophenyl)methanone (33) – Yield: 45 mg, 
42%. 1H NMR: δ 7.76 (d, J = 8.8 Hz, 2H), 7.39 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 6.89-
6.87 (m, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 3.84-3.82 (m, 4H), 3.30-3.27 (m, 4H) ppm. 
13C NMR: δ 194.1, 153.8, 152.3, 148.8, 132.2, 131.2, 128.4, 124.5, 113.3, 112.3, 
109.8, 66.6, 56.1, 56.0, 47.7 ppm. HRMS (ESI) m/z calculated for C19H22O4N [(M + 
H)+]: 328.1543, found 328.1538. 
IV. Miscellaneous compounds: 
 
Procedure for the synthesis of oxime product (34) 
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To a solution of 133 mg of bis(4-methoxyphenyl)methanone (1 eq.) in MeOH (10 mL) 
was added 0.22 mL of pyridine (5 eq.) The solution was then charged with 153 mg of 
hydroxylamine hydrochloride (4 eq.) and was allowed to stir at room temperature for 
36 h. The mixture was concentrated and the solid obtained was dissolved in DCM 
(20 mL). The solution was washed with 1M HCl solution (20 mL), saturated NaHCO3 
solution (20 mL), brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The 
product was purified using flash column chromatography. Ethyl acetate and hexanes 
were used as eluent (1:6).  Yield: 79 mg, 56%. 1H NMR: δ 7.44-7.40 (m, 4H), 6.99 
(d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 3.86 (s, 3H), 3.82 (s, 3H) ppm. 13C 
NMR: δ 160.7, 160.0, 157.0, 131.2, 129.5, 129.3, 125.0, 113.8, 113.6, 55.4, 55.3 
ppm. HRMS (ESI) m/z calculated for C15H16NO3 [(M + H)+]: 258.1130, found 
258.1123.  
 
Procedure for the synthesis of the hydrazone product (35): 
In a heavy-walled glass vial sealed with a Teflon septum, 40 mg of bis(4-
methoxyphenyl)methanone (1 eq) was dissolved in MeOH (5 mL) was mixed with 
160 mg of (4-nitrophenyl)hydrazine (4 eq.) and 0.66 mL of pyridine (5 eq.). The 
solution was irradiated with microwave for 5 min at 150 oC at 35W. The mixture was 
concentrated and the solid obtained was dissolved in DCM (20 mL). The solution 
was washed with 1M HCl solution (20 mL), saturated NaHCO3 solution (20 mL), 
brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The product was 
N
MeO OMe
NH
NO2
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purified using flash column chromatography. Ethyl acetate and hexanes were used 
as eluent (1:8).  Yield: 63 mg, 79%. 1H NMR: δ 8.15 (d, J = 9.2 Hz, 2H), 7.89 (s, 1H), 
7.56 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 7.08 (d, J 
= 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 3.91 (s, 3H), 3.85 (s, 3H) ppm. 13C NMR: δ 
160.6, 160.5, 149.6, 148.8, 139.9, 132.2, 130.5, 130.3, 128.6, 126.1, 123.8, 115.2, 
115.2, 113.7, 113.5, 111.8, 55.4, 55.3 ppm. HRMS (ESI) m/z calculated for 
C21H20O4N3 [(M + H)+]: 378.1448, found 378.1444.  
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